Table 6. Survival analysis of PLCE1 mRNA expression and serum AFP levels in HBV-related HCC patients from GSE14520.
| Variables | Patients (n=218) | DFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of events (%) | MST(months) | Adjusted HR(95% CI) | Adjusted P§ | No. of events (%) | MST(months) | Adjusted HR(95% CI) | Adjusted P§ | ||
| PLCE1 level | |||||||||
| Low | 109 | 52 (47.7) | 57 | 1 | 31 (28.4) | NA | 1 | ||
| High | 109 | 69 (63.3) | 29 | 1.688 (1.151-2.476) | 0.007 | 53 (48.6) | 53 | 2.317 (1.448-3.706) | 0.0005 |
| AFP (ng/ml)φ | |||||||||
| ≤300 | 118 | 65 (55.1) | 48 | 1 | 40 (33.9) | 56 | 1 | ||
| >300 | 96 | 55 (57.3) | 35 | 1.001 (0.693-1.446) | 0.995 | 43 (44.8) | 49 | 1.234 (0.794-1.918) | 0.351 |
Notes: φ Information of AFP was unavailable in 4 patients; § Adjustment for age, gender, cirrhosis, BCLC stage, serum AFP levels; DFS, disease-free survival; OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval.